Calithera Biosciences【CALA】銘柄情報 | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Calithera Biosciences Inc (CALA) 銘柄情報

Calithera Biosciences Inc (CALA)

0.20

0.00

(0.00%)

終了 12月1日 6:00AM

0.00

0.00

(0.00%)

取引時間後: -

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.20

買値

0.16

売値

0.35

出来高

-

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

0.20

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

-

発行済株式数

4,872,497

配当利回り

-

PER

0.00

1 株当たり利益 (EPS)

-4.37

歳入

-

純利益

-21.29M

Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumo... Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.calithera.com

本社

Wilmington, Delaware, USA

設立

-

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a...

Calithera Biosciences Announces Update on Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or...

Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive...

Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-mutated Squamous Lung Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that...

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its...

Calithera Biosciences to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced...

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
BSLKBolt Projects Holdings Inc	US$ 0.71 (139.86%)	80.81M
PRZOParaZero Technologies Ltd	US$ 1.24 (94.14%)	205.02M
AIEVThunder Power Holdings Inc	US$ 0.47 (87.25%)	122.71M
PASGPassage Bio Inc	US$ 1.13 (69.52%)	15.44M
EPOWSunrise New Energy Company Ltd	US$ 1.06 (45.21%)	314.9k
APLTApplied Therapeutics Inc	US$ 2.03 (-76.31%)	42.74M
TGLTreasure Global Inc	US$ 0.2944 (-29.08%)	1.83M
PROCProcaps Group SA	US$ 1.51 (-27.75%)	98.71k
SHOTWSafety Shot Inc	US$ 0.104 (-20.00%)	1.43k
MONDMondee Holdings Inc	US$ 0.7102 (-19.59%)	297.61k
PRZOParaZero Technologies Ltd	US$ 1.24 (94.14%)	205.02M
NVDANVIDIA Corporation	US$ 138.25 (2.15%)	141.86M
AIEVThunder Power Holdings Inc	US$ 0.47 (87.25%)	122.71M
RGTIRigetti Computing Inc	US$ 3.05 (27.08%)	116.98M
MARAMARA Holdings Inc	US$ 27.42 (1.86%)	89.54M

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2年前

maybe soon will see something

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2年前

maybe soon will see something

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2年前

ALERTS100%to10000%GAIN

ALERTS100%to10000%GAIN 2年前

cala soon something

Renee

CALA delisted from the Nasdaq to the OTC:

https://otce.finra.org/otce/dailyList?viewType=Additions

kzivann

kzivann 2年前

CALA dissolving. https://quantisnow.com/insight/3950020

Mr. Zen

Mr. Zen 2年前

Calithera continued to advance multiple vacuolar protein sorting-associated protein 4A (VPS4A) and VPS4B inhibitors through lead optimization and plans to share updates on this program by the end of 2022.

Nealio

CALA - continues upward. 100% gain in last month, very good swing play. Drug data was good...float is very low at 4.X M shares.

Nealio

CALA in play! Drug data and earnings report. Should move even higher on this news.

Nealio

Chart looks very good atm.

Nealio

Could be the start of a big run; or not. We shall see; with recent good news, I like the chances. Good luck to all!

ttottip

ttottip 3年前

ttottip

ttottip 3年前

Good morning all! Hoping for a reversal today.

ttottip

ttottip 3年前

I'm not hesitating to buy at these levels!

bandit007

bandit007 3年前

Took a few here. $CALA

kzivann

kzivann 3年前

Moving after hours.

CALA

crudeoil24

crudeoil24 3年前

Calithera Biosciences shares are trading higher after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and a $4 price target.

CALA

TheFinalCD

TheFinalCD 3年前

big move 45-74

$CALA

glens0

$CALA .58 w/ $3 price upgrade out by Leerink

Eagle1

crudeoil24

crudeoil24 3年前

Company discontinued its KEAPSAKE clinical trial.

Eagle1

Hi why the drop here?

0210

Calithera Biosciences CALA Q3 EPS $(0.15) Beats $(0.23) Estimate, Sales $6.75M, and a 53.13 percent increase over losses of $(0.32) per share from the same period last year.

4:42 pm ET November 9, 2021 (Benzinga)
Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 34.78 percent. This is a 53.13 percent increase over losses of $(0.32) per share from the same period last year. The company reported $6.75 million in sales this quarter.

0210

right-on-the-money...-54% to $0.86-0.87, from $1.90 on 21x dmav (of only 1,082,848 daily moving average volume).

SOURCE: https://ih.advfn.com/stock-market/NASDAQ/calithera-biosciences-CALA/historical

willlbone

willlbone 3年前

Bid at 60% drop.

TheFinalCD

TheFinalCD 3年前

$CALA -40%

Calithera Biosciences, Inc. | Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

https://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-announces-decision-discontinue-keapsake

Elgordo84

Elgordo84 4年前

I’m expecting earnings to be on the up tomorrow
Let’s go $CALA

Elgordo84

Elgordo84 4年前

Looks like no one is paying attention
$CALA I guess is you and me!!!
Perfect for the run
While no one is watching.......

Elgordo84

Elgordo84 4年前

Ok hello $CALA
I LIKE WHAT I SEE HERE!!!!
Let’s take this for a ride...
$CALA LETS GO —————>

trade-stock000

trade-stock000 4年前

Cala when is the data due date? Thx

oaps222

oaps222 4年前

Thanks for the info.
Geez~~, what a move. I wish I knew it last Thursday! LOL

In any event, congratulations, if you already got in ARTL!

trade-stock000

trade-stock000 4年前

A-R-T-L is the one to watch (: PT $8-10
Add on correction price, read few post over there abt data and cocrystal CBD molecules. Apart from that it's focused on Lipid therapy the next frontier in Oncology.

oaps222

oaps222 4年前

Very good point, but be careful. The market is crazy. I can see some (big?) corrections in the near future.

oaps222

oaps222 4年前

From the recent 13G Filings, Adage Capital has reported its 4,000,000 shares of CALA (5.67% ownership) on Jan 13, 2021.

trade-stock000

trade-stock000 4年前

Yeah but in Jan that was not much of an update, that´s why stock plummeted, company needs more time.

Jan option price rose becoz of that reason, now fade out. Will visit this ticker later, for now it´s waste of cash esp when whole market is running nut

oaps222

oaps222 4年前

Was it on Jan 15-17, not Feb 15-17?
http://www.calithera.com/wp-content/uploads/2021/01/Arginase-1158-203-Poster.pdf

trade-stock000

trade-stock000 4年前

IV surges in the event of future price move. $5 call for Feb 19 it seems someone very bullish abt this stock and bot calls. Article u cited it's from Jan-13th, today its 13th Feb (:, unless next week something comes out which is highly unlikely.

oaps222

oaps222 4年前

I was doing a DD on CALA and found the following. I don't quite understand it. Can you share your thoughts on this?
"Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options"

https://finance.yahoo.com/news/implied-volatility-surging-calithera-biosciences-134001483.html

trade-stock000

trade-stock000 4年前

2.42 or lower test first before go up i hope

trade-stock000

trade-stock000 4年前

CALA on Feb 15-17 presenting Biliary-Tract Cancer-Data-could do-vroomvroom

jondoeuk

jondoeuk 4年前

ASH abstract https://ash.confex.com/ash/2020/webprogram/Paper137266.html

ClayTrader

ClayTrader 5年前

* * $CALA Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

cashbyers

cashbyers 5年前

9.5M block trade today @ $4.45.. 17% stake or $42M investment...

ClayTrader

ClayTrader 5年前

* * $CALA Video Chart 11-19-19 * *

Link to Video - click here to watch the technical chart video

jonny_red

jonny_red 5年前

4 Penny Stocks To Watch In November After Latest Milestones

$GTBP $CALA $AVDL $BLCM

https://www.transparenttraders.me/2019/11/4-penny-stocks-to-watch-in-november.html

cashbyers

cashbyers 5年前

Long CALA @ $2.60

buypumps

buypumps 5年前

Conference call Monday also. Could push to 3.90 area.

Zmill

TA of CALA https://msmoneymoves.com/2019/07/12/calithera-initiates-potential-buying-opportunity/

CashBowski

CashBowski 5年前

CALA going to close the gap today.

Zmill

Research mentioning CALA https://wordpress.com/block-editor/post/msmoneymoves.com/11262

Calithera Biosciences

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約